PT-141 Nasal Spray (10mg)
Especificaciones técnicas
| Pureza (HPLC) | ≥99% (HPLC) |
| Número CAS | 189691-06-3 |
| Forma | White lyophilized powder |
| Almacenamiento | -20°C |
| Secuencia | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Peso molecular | 1,025.21 g/mol |
| Forma salina | Acetate |
| Solubilidad | Soluble in water |
PT-141 Nasal Spray (10mg)
Precio de lista en EUR · HU, SK, CZ, PL
- Eurozone (EUR)243,00 EUR
- Hungría (HU)243,00 EUR≈ 97 200 Ft
- Eslovaquia (SK)243,00 EUR
- Chequia (CZ)243,00 EUR≈ 6 075 Kč
- Polonia (PL)243,00 EUR≈ 1032,75 zł
Mismo precio de lista en EUR para envío a Hungría, Eslovaquia, República Checa y Polonia. El pago se cobra en EUR.
HUF/CZK/PLN indicativos convertidos desde EUR; Eslovaquia usa EUR. Tasas aproximadas. Cobro en EUR.
Bremelanotide (PT-141) pre-formulated as a nasal spray for libido and melanocortin research. 10mg total.
Estrictamente para investigación de laboratorio.
No apto para consumo humano, uso veterinario ni diagnóstico.
From the Peptide Explorer
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Key Mechanisms
- ›MC4R agonism (central, hypothalamic)
- ›MC3R partial agonism
- ›CNS-mediated arousal pathway
- ›Dopaminergic downstream signaling
- ›Independent of vascular mechanisms
Primary Research Areas
- ›Hypoactive sexual desire
- ›Melanocortin receptor pharmacology
- ›Central arousal pathways
- ›Female sexual dysfunction
Key Research Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Overview
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Origin: Derived from Melanotan II; developed by Palatin Technologies
Mechanism of Action
- MC4R agonism (central, hypothalamic)
- MC3R partial agonism
- CNS-mediated arousal pathway
- Dopaminergic downstream signaling
- Independent of vascular mechanisms
Primary Research Areas
- Hypoactive sexual desire
- Melanocortin receptor pharmacology
- Central arousal pathways
- Female sexual dysfunction
Key Published Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
PT-141 Nasal Spray (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Especificaciones de investigación
Synthesized for strict analytical consistency. Verified via HPLC/MS.Ver estándares de calidad →
Manipulación y almacenamiento
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water